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Conclusions: The aforementioned clinical outcomes and com-
parative analysis is essential for furthering our understanding of
the factors which inﬂuence patient outcomes in the treatment of
cartilage injury by autologous chondrocyte implantation therapy
such as MACI.
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EARLY REDUCTION IN ULCER COMPLICATIONS WITH
LUMIRACOXIB COMPARED WITH NSAIDS: DATA FROM
TARGET
C.J. Hawkey1, W. Weinstein2, G. Krammer3, V. Murphy3,
K. Stricker3
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Purpose: A 79% reduction in upper gastrointestinal (GI) ul-
cer complications has been reported for lumiracoxib compared
with nonsteroidal anti-inﬂammatory drugs (NSAIDs) (naproxen
or ibuprofen) over 52 weeks in the non-aspirin population of
the Therapeutic Arthritis Research and Gastrointestinal Event
Trial (TARGET). However, guidelines indicate that these agents
should be used for the shortest possible duration. We investi-
gated how early after the start of treatment a signiﬁcant beneﬁt
of lumiracoxib could be detected in TARGET.
Methods: TARGET randomized 18 325 patients >50 years of
age with osteoarthritis (OA) to receive lumiracoxib 400 mg once
daily (4x the recommended dose for OA) vs ibuprofen 800 mg
three times daily or naproxen 500 mg twice daily for 52 weeks in
one of two sub-studies. Randomization was stratiﬁed for age and
low-dose aspirin use. The primary analysis population included
patients not taking low-dose aspirin, comprising n=6950 patients
treated with lumiracoxib and n=6968 with NSAIDs (naproxen,
n=3537; ibuprofen, n=3431). The primary endpoint was the cu-
mulative incidence of blindly and independently adjudicated def-
inite or probable upper GI ulcer complications. The secondary
endpoint was the incidence of deﬁnite or probable upper GI ulcer
complications and symptomatic ulcers (all ulcers). In these anal-
yses, pointwise 95% conﬁdence intervals (CI) were generated
for the between-treatment differences in Kaplan-Meier estimates
(KMEs) for all ulcers and ulcer complications in the non-aspirin
population.
Results: Based on the upper 95% CIs for the difference in
Kaplan-Meier estimates, in the non-aspirin population there was
a signiﬁcant reduction in all ulcers by Day 8 with lumiracoxib
compared with NSAIDs. For ulcer complications, a signiﬁcant re-
duction with lumiracoxib compared with NSAIDs occurred by Day
16. When analyzed by sub-study, the advantage of lumiracoxib
on all ulcers occurred as early as by Day 6 versus naproxen
(Figure 1) and by Day 32 versus ibuprofen. For ulcer complica-
tions, a signiﬁcant reduction was seen with lumiracoxib by Day
14 versus naproxen and Day 33 versus ibuprofen.
Abstract 260 – Table 1. Efﬁcacy of lumiracoxib in the disease severity subgroups at 13 week
Efﬁcacy variable Pair wise Comparison High severity group Medium severity group Low severity group
Estimated difference P-value Estimated difference P-value Estimated difference P-value
(95% CI of difference) (95% CI of difference) (95% CI of difference)
OA pain Lumiracoxib vs placebo -9.30 (-13.25,-5.34) <0.001 -5.48 (-8.41,-2.55) <0.001 -4.74 (-8.44,-1.03) 0.012
Celecoxib vs placebo -6.70 (-11.22,-2.19) 0.004 -4.76 (-8.15,-1.38) 0.006 -4.74 (-9.03,-0.45) 0.030
Lumiracoxib vs celecoxib -2.59 (-6.44,1.25) 0.186 -0.71 (-3.67,2.24) 0.636 0.00 (-3.70,3.71) 0.998
Patient’s global assessment Lumiracoxib vs placebo -9.83 (-13.74,-5.93) <0.001 -8.09 (-10.99,-5.20) <0.001 -4.21 (-7.87,-0.55) 0.024
of disease activity Celecoxib vs placebo -6.63 (-11.09,-2.18) 0.004 -6.10 (-9.45,-2.75) <0.001 -3.47 (-7.72,0.77) 0.109
Lumiracoxib vs celecoxib -3.20 (-7.00,0.60) 0.099 -1.99 (-4.91,0.93) 0.181 -0.74 (-4.40,2.93) 0.694
WOMAC™ total score Lumiracoxib vs placebo -8.08 (-10.86,-5.30) <0.001 -5.26 (-7.32, -3.19) <0.001 -4.11 (-6.72,-1.50) 0.002
Celecoxib vs placebo -5.62 (-8.79,-2.44) <0.001 -4.94 (-7.32,-2.56) <0.001 -3.24 (-6.26,-0.22) 0.036
Lumiracoxib vs celecoxib -2.47 (-5.17,0.24) 0.074 -0.32 (-2.40,1.77) 0.767 -0.87 (-3.48,1.74) 0.513
Figure 1
Conclusions: The long-term GI beneﬁt of lumiracoxib compared
with traditional NSAIDs has been demonstrated previously. How-
ever, even when given for short periods, the selective COX-2
inhibitor lumiracoxib appears to have signiﬁcant GI safety advan-
tages over nonselective NSAIDs.
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Purpose: To evaluate if the efﬁcacy of lumiracoxib 100 mg od and
celecoxib 200 mg od differed in patients with knee osteoarthritis
(OA) as a function of baseline disease severity.
Methods: Data from two 13-week, multicenter, randomized,
double-blind, double-dummy, placebo-controlled studies compar-
ing lumiracoxib 100 mg od with celecoxib 200 mg od and placebo
were combined for efﬁcacy analysis based on baseline disease
severity. The co-primary endpoints included assessment of OA
pain intensity in the target knee (VAS), patient’s global assess-
ment of disease activity (VAS) and WOMAC™ LK3.1 total score
at study end. Disease severity at baseline was deﬁned as high,
medium, or low using the median of the baseline values for
each of the three primary assessments. A patient was classiﬁed
with high baseline disease severity if all 3 baseline values were
greater than their respective median, medium baseline disease
severity if 1 or 2 baseline values were greater than their median
and low baseline disease severity if none of the 3 baseline
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values were greater than the respective median. The difference
in treatment effect on baseline disease severity sub-group was
analyzed using analysis of covariance (ANCOVA).
Results: In total, 3235 patients comprised the ITT population of
the pooled efﬁcacy analysis. Out of these, 3214 patients were
included in the disease severity analysis [low (n = 923), medium
(n =1456) and high (n=835)]. Mean OA pain at baseline was 79
mm in the high disease severity, 65 mm in the medium disease
severity and 53 mm in the low disease severity subgroup. The
greatest reduction in OA pain intensity with lumiracoxib and
celecoxib compared to placebo, was seen in the highest disease
severity group (lumiracoxib [-9.30mm; p≤0.001] celecoxib [-6.70
mm; p=0.004]) as compared to the medium disease severity
group (lumiracoxib [-5.48; p≤0.001], celecoxib [-4.76; p=0.006])
and low disease severity group (lumiracoxib [-4.74 mm; p=0.012]
celecoxib [-4.74 mm; p=0.030]). Similar results were seen for
patient’s global assessment of disease activity and the functional
status, assessed by WOMAC™ LK3.1 total score (Table 1).
Conclusions: Lumiracoxib provides effective pain relief and im-
provement of symptoms in all subgroups of OA patients deﬁned
by disease severity at baseline. However, there is a trend for
greatest efﬁcacy in the subgroups of patients with highest dis-
ease severity.
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IS SELF-REPORTED IMPROVEMENT IN
OSTEOARTHRITIS PAIN AND DISABILITY REFLECTED IN
OBJECTIVE MEASURES?
G. Baltaci, V.B. Tunay
Hacettepe University, Ankara, Turkey
Purpose: Osteoarthritis (OA) is perceived as a major public
health problem, and today, various clinical outcome methods are
used to see the improvement of the management for this condi-
tion. The purpose of this study was to determine if self-reported
improvements in pain and function correlate with improvement in
objective measures of disease in OA.
Methods: Eighty female patients (mean age: 52.3 ± 8.7 years)
with bilateral OA of the knee were assessed by some tests includ-
ing [sociodemographics, body mass index (28.34± 4.88 kg/m2,
and a self-reported questionnaire-Western Ontario and McMas-
ter University Osteoarthritis Index (WOMAC) scores] and physi-
cal [muscular strength by ISOMED 2000 isokinetic dynamometry,
proprioception by determining deﬁcit at the knee joint using by
Functional Squat System, Timed Get up and Go (TGG) for walk-
ing duration, visual analog scale for measuring the intensity of
the present pain, warmth, effusion] and clinical examination of
the knees (Altman Grade II). Subjects received closed kinetic
chain in clinic and home-based structured exercise program 5
days a week for 4 weeks, totally 20 sessions. All tests were done
before and after the 4-week treatment period.
Results: There were no signiﬁcant correlation between pain at
rest and night, during activity and proprioception deﬁcit in left (r=
0.05, r= -0.16, and r= -0.14; p>0.05) and right (r=0.22, r=0.07,
and r=0.19; p>0.05) knee joint pre-treatment, respectively. Be-
sides; there were found a correlation after treatment between
pain at rest and night, with activity and proprioception deﬁcit in
left (r= 0.32, r= -0.37, and r= -0.29; p<0.05) and right (r=0.53,
r=0.39, and r=0.2; p<0.05) knee. The peak torque of isokinetic
muscular strength and proprioception of participants were im-
proved after rehabilitation. Of eighty eligible patients, WOMAC
scores were improved after immediate treatment in clinical-based
exercise group, 46.4% and 56.4% reported the improvement
in pain and function, respectively. However, improvements in
WOMAC scores were not associated with improvements in any
of the other measures (Left knee peak torque (PT), r= -0.28 and
right knee PT, r= -0.29; p>0.05 for all). There was a signiﬁcant
correlation between proprioception scores and TGG test either
before (r= -0.31; p=0.016) (p<0.05) or after (r= -0.4141; p=0.001)
(p<0.01) rehabilitation. The ﬁndings at 4th weeks after enroll-
ment were that the quadriceps strength was slightly increased
but the walking duration was decreased when compared with
the initial assessment. An exercise frequency of 20 sessions in
a month was sufﬁcient to improve muscle strength and walking
distance.
Conclusions: Seventy-three of participants reported signiﬁcant
improvements in WOMAC pain and disability after treatment.
Both closed kinetic chain and home-based exercise program
produce a signiﬁcant improvement in strength and walking ability,
especially in the ﬁrst months. In the assessment of knee OA,
muscle strength, proprioception, and walking ability can be used
to measure the effect of improvement of pain and disability after
treatment programs.
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Purpose: Results of studies that have evaluated obesity as a
risk factor for the progression of structural damage in knees with
osteoarthritis (OA) are conﬂicting. However, researchers who de-
sign clinical trials for structure-modifying drugs for OA (SMOADs)
often consider “weighting” the study cohort with patients with a
higher body mass index (BMI), in the hope of enriching for pa-
tients who will have more rapidly progressive OA. We asked
whether, among obese patients with knee OA, a higher BMI was
associated with an increased rate of joint space narrowing (JSN).
Methods: In 60 women with symptomatic OA (KLG2 or 3 in a
standing AP radiograph) and a mean BMI (± SD) of 37.2 ±
5.1, medial tibiofemoral JSN over 12 months were measured in
modiﬁed Lyon schuss (mLS) radiographs. We compared these
ﬁndings to those in 81 age-matched, non-obese, asymptomatic,
KLG0 women (BMI = 23.5 ± 2.3).
Results: Among the OA patients, a higher BMI tended to be
associated with a higher KLG. Mean BMI was 36.0 ± 4.5 in
KLG2 patients and 38.4 ± 5.4 in KLG3 patients (p=0.06). Mean
JSN in the 81 controls was 0.02 ± 0.25 mm (p=0.51), whereas
in the 30 KLG2 knees and 30 KLG3 knees, mean JSN was 0.12
± 0.31 mm (p=0.08 vs. KLG0) and 0.32 ± 0.50 mm (p<0.0001
vs. KLG0), respectively. KLG3 knees were more homogeneous
with respect to JSN than KLG2 knees (SRM = 0.64 vs. 0.39).
BMI was not related to JSN in OA knees.
Conclusions: Among these OA patients, with a BMI ≥ 30,
there was no evidence that progressively higher BMIs were
accompanied by a progressively increasing rate of JSN. We
will determine whether a longer period of observation will yield
different results. In the mLS views, 12 months was sufﬁcient to
detect JSN in KLG2/3 knees, relative to knees of nonarthritic
controls (p=0.0001). Because none of our OA patients had a
BMI <30, this study cannot not address the question whether
JSN is more rapid in overweight or obese subjects than in knee
OA patients of normal weight. For an SMOAD trial, these data
suggest that recruitment of patients with a BMI much beyond 30
will not enrich the sample in subjects who will exhibit more rapid
JSN than would patients with a BMI of 30.
